BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Meng Y, Wang L, Liu Z, Li J, Dong W. Associations between the <i>NUDT15</i> R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: A meta-analysis. Onco Targets Ther. 2018;11:8309-8317. [PMID: 30538500 DOI: 10.2147/ott.s177007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Sedano R, Hogan M, Mcdonald C, Aswani-omprakash T, Ma C, Jairath V. Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab362] [Reference Citation Analysis]
2 Poon K, Imran IIB, Chew SK, Tan P, Tan KM. A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population. BMC Res Notes 2022;15. [DOI: 10.1186/s13104-021-05821-3] [Reference Citation Analysis]
3 Daniel LL, Dickson AL, Chung CP. Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine. Clin Rheumatol 2021;40:65-73. [PMID: 32617765 DOI: 10.1007/s10067-020-05258-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol 2022;22:44. [PMID: 35120446 DOI: 10.1186/s12876-021-02074-z] [Reference Citation Analysis]
5 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Pai AA, Mohan A, Benjamin ESB, Illangeswaran RSS, Xavier Raj I, Janet NB, Arunachalam AK, Kavitha ML, Kulkarni U, Devasia AJ, Fouzia NA, Abraham A, Srivastava A, George B, Mathews V, Korula A, Balasubramanian P. NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. Pharmgenomics Pers Med 2021;14:1303-13. [PMID: 34629890 DOI: 10.2147/PGPM.S325813] [Reference Citation Analysis]
7 Sedano R, Hogan M, Mcdonald C, Aswani-Omprakash T, Ma C, Jairath V. Underrepresentation of Minorities and Underreporting of Race and Ethnicity in Crohn's Disease Clinical Trials. Gastroenterology 2021:S0016-5085(21)03585-X. [PMID: 34592174 DOI: 10.1053/j.gastro.2021.09.054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548 [PMID: 31210708 DOI: 10.3748/wjg.v25.i21.2539] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
9 Zhou Y, Wang L, Zhai XY, Wen L, Tang F, Yang F, Liu XT, Dong L, Zhi LJ, Shi HY, Hao GX, Zheng Y, Jacqz-Aigrain E, Wang TY, Zhao W. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 2020;86:1519-27. [PMID: 32077136 DOI: 10.1111/bcp.14258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]